Healthcare professionals
Media centre and events
Careers

Facebook
Twitter
Instagram
LinkedIn
YouTube

About us +
About us

We are ViiV Healthcare: 100% dedicated to HIV medicines and research and completely focused on people affected by HIV and AIDS.
Visit the About us section

Our leadership

Corporate ethics and compliance

Social Media at ViiV Healthcare

Contact our team
Our HIV medicines +
Our HIV medicines
Learn about our HIV medicines

Information for healthcare professionals
HIV research +
HIV research

We are dedicated to treating, preventing and hopefully one day, curing HIV. Find out more about our latest research.
Learn about our HIV research

Medicines in development

Innovation in HIV science
Community engagement +
Community engagement

We work actively with communities affected by HIV and AIDS around the world. Read about our community engagement initiatives.
How we support the HIV community

Positive Action

Positive Perspectives research
Living with HIV +
Living with HIV
Starting your HIV journey

You and your HIV treatment

A healthy life with HIV

Talking to your doctor
Ending HIV +
Ending HIV

We are the only pharmaceutical company solely focused on curing HIV and AIDS, but of course, none of what we do can be achieved alone – we believe in the power of partnership.
We strive to put an end to HIV

Our commitment to global health

HIV stigma

Our stories

HIV Implementation Science

Healthcare professionals
Media centre and events
Careers

Facebook
Twitter
Instagram
LinkedIn
YouTube

OPEN

CONTACT OUR TEAM

If you have a general inquiry about ViiV Healthcare,
please contact our corporate headquarters:

ViiV Healthcare
980 Great West Road
Brentford
Middlesex
TW8 9GS
UK

Tel: +44 (0)20 8380 6200

Or fill out the form below

Our Privacy Notice outlines
how GSK handles the processing
of personal information when
dealing with your enquiry,
complaint or adverse event report:

Report an adverse event

To report a suspected side
effect, please use this link
hosted on gsk.com.

If you have questions about
a specific medical condition,
please consult a healthcare
professional.

Additional contact information:

Journalists / Media

Corporate Press Office

tel: +44 (0)20 8380 6200

Alternatively, you can contact us on:

UK – Catherine Hartley
tel: +447909002403

US – Audrey Abernathy
tel: +1 919 605 4521

Investors

ViiV Healthcare does not offer shares, so
investors and analysts should contact
GlaxoSmithKline's Investors Relations
team: www.gsk.com/en-gb/investors/

Business Development

Please contact Dr. Trevor Scott, VP and Head,
Business Development and Alliances
viiv.partnering@viivhealthcare.com.

NP-GBL-HVX-COCO-220010 November 2021.

Connect with us

ViiV Healthcare

980 Great West Road
Brentford
Middlesex
TW8 9GS
UK
Tel. +44 (0)20 8380 6200

Terms of use
Cookie policy
Privacy notice
Modern Slavery Statement
Sitemap
All our locations
Our Clinical Trial Register

Report an adverse event

To report a suspected side effect, please use our online reporting form hosted on gsk.com.

NP-GBL-HVX-COCO-220037 November 2021

YOU ARE LEAVING THE SITE

You are about to leave a ViiV Healthcare website. By clicking this link, you will be taken to a website that is independent from ViiV Healthcare. The site you are linking to is not controlled or endorsed by ViiV Healthcare and ViiV Healthcare is not responsible for the content provided on that site.

NP-GBL-HVX-COCO-220042 | November 2021

Cancel Accept

Select Country & Language

Australia

English
Canada

English Français
Netherlands

English
Switzerland

English

Français

Deutsch
France

Français
United States

English
Italy

Italiano
Japan

日本人
Germany

Deutsch
España

Español

You are accessing historic archive material

This is an archived press release which may not reflect current medical knowledge and should not be used as a source of information on the present label, safety data or efficacy data for ViiV Healthcare products and/or their uses. Please refer to your nationally approved label or summary of product characteristics for up-to-date product information.

I understand